XBH104

XBH104 is a preclinical-stage therapeutic candidate being developed by GV20 Oncotherapy for the treatment of lung cancer. It is uniquely characterized by a dual-modality mechanism of action, functioning as both an antibody-drug conjugate (ADC) and a T-cell engager. This approach is designed to combine the targeted delivery of a cytotoxic payload directly to tumor cells with the recruitment and activation of T-cells to the tumor site, potentially enhancing anti-tumor efficacy compared to single-modality agents. As of early 2026, specific molecular targets and the structural configuration of the molecule remain undisclosed by the developer.